(PRGO) Perrigo - Ratings and Ratios
Cough Relief, Infant Formula, Heartburn Relief, Pain Relievers, Skin Care
PRGO EPS (Earnings per Share)
PRGO Revenue
Description: PRGO Perrigo
Perrigo Company PLC is a leading provider of over-the-counter (OTC) health and wellness products globally, operating primarily through its Consumer Self-Care Americas and Consumer Self-Care International segments. The companys diverse product portfolio includes upper respiratory, nutrition, digestive health, pain and sleep-aids, oral care, and womens health products, among others, marketed under various well-known brands.
From a business perspective, Perrigos products are sold through multiple channels, including retail drug, supermarket, and mass merchandise chains, e-commerce stores, wholesalers, and pharmacies. The companys brand portfolio, which includes Compeed, Good Sense, Mederma, and others, provides a strong foundation for its market presence. Notably, the companys ability to offer contract manufacturing services adds another revenue stream.
To further analyze Perrigos performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin are crucial. For instance, a steady increase in revenue, coupled with stable or expanding gross margins, could indicate a healthy business model. Additionally, metrics like Return on Equity (ROE) and Debt-to-Equity ratio provide insights into the companys financial health and leverage. Given Perrigos current ROE of -4.05%, it may indicate challenges in generating profits from shareholder equity. The forward P/E ratio of 9.29 suggests the markets expectations for future earnings growth.
From a valuation perspective, analyzing Perrigos market capitalization of $3858.98M USD, along with its price-to-earnings ratio and other multiples, can help determine if the stock is undervalued or overvalued relative to its peers and the broader market. Comparing these metrics with industry averages and historical data can provide a more comprehensive view of the companys valuation.
PRGO Stock Overview
| Market Cap in USD | 3,232m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1991-12-16 |
PRGO Stock Ratings
| Growth Rating | -52.3% |
| Fundamental | 48.9% |
| Dividend Rating | 66.5% |
| Return 12m vs S&P 500 | -33.6% |
| Analyst Rating | 3.80 of 5 |
PRGO Dividends
| Dividend Yield 12m | 4.92% |
| Yield on Cost 5y | 2.86% |
| Annual Growth 5y | 4.17% |
| Payout Consistency | 100.0% |
| Payout Ratio | 49.0% |
PRGO Growth Ratios
| Growth Correlation 3m | -71.5% |
| Growth Correlation 12m | -1.2% |
| Growth Correlation 5y | -90.4% |
| CAGR 5y | -15.22% |
| CAGR/Max DD 3y | -0.36 |
| CAGR/Mean DD 3y | -0.63 |
| Sharpe Ratio 12m | -1.22 |
| Alpha | 0.00 |
| Beta | 0.696 |
| Volatility | 32.58% |
| Current Volume | 1920.7k |
| Average Volume 20d | 1372.5k |
| Stop Loss | 20.4 (-3.5%) |
| Signal | -1.00 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-80.3m TTM) > 0 and > 6% of Revenue (6% = 259.6m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 0.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 34.42% (prev 33.22%; Δ 1.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 366.2m > Net Income -80.3m (YES >=105%, WARN >=100%) |
| Net Debt (3.38b) to EBITDA (611.4m) ratio: 5.53 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (138.2m) change vs 12m ago 0.80% (target <= -2.0% for YES) |
| Gross Margin 35.73% (prev 35.93%; Δ -0.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.22% (prev 42.59%; Δ -0.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.58 (EBITDA TTM 611.4m / Interest Expense TTM 179.3m) >= 6 (WARN >= 3) |
Altman Z'' 1.26
| (A) 0.15 = (Total Current Assets 2.62b - Total Current Liabilities 1.13b) / Total Assets 10.09b |
| (B) -0.22 = Retained Earnings (Balance) -2.27b / Total Assets 10.09b |
| (C) 0.03 = EBIT TTM 282.6m / Avg Total Assets 10.25b |
| (D) 0.80 = Book Value of Equity 4.47b / Total Liabilities 5.62b |
| Total Rating: 1.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.94
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 3.97% = 1.99 |
| 3. FCF Margin 5.93% = 1.48 |
| 4. Debt/Equity 0.82 = 2.17 |
| 5. Debt/Ebitda 6.02 = -2.50 |
| 6. ROIC - WACC (= 3.78)% = 4.72 |
| 7. RoE -1.81% = -0.30 |
| 8. Rev. Trend -65.05% = -4.88 |
| 9. EPS Trend -14.89% = -0.74 |
What is the price of PRGO shares?
Over the past week, the price has changed by -4.48%, over one month by -7.12%, over three months by -18.57% and over the past year by -21.29%.
Is Perrigo a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PRGO is around 18.04 USD . This means that PRGO is currently overvalued and has a potential downside of -14.62%.
Is PRGO a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PRGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.3 | 62.1% |
| Analysts Target Price | 34.3 | 62.1% |
| ValueRay Target Price | 20.1 | -4.7% |
Last update: 2025-09-04 04:45
PRGO Fundamental Data Overview
CCE Cash And Equivalents = 454.2m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 7.1633
P/S = 0.7471
P/B = 0.7226
P/EG = 1.1418
Beta = 0.467
Revenue TTM = 4.33b USD
EBIT TTM = 282.6m USD
EBITDA TTM = 611.4m USD
Long Term Debt = 3.62b USD (from longTermDebt, last quarter)
Short Term Debt = 65.3m USD (from shortTermDebt, last quarter)
Debt = 3.68b USD (Calculated: Short Term 65.3m + Long Term 3.62b)
Net Debt = 3.38b USD (from netDebt column, last quarter)
Enterprise Value = 6.46b USD (3.23b + Debt 3.68b - CCE 454.2m)
Interest Coverage Ratio = 1.58 (Ebit TTM 282.6m / Interest Expense TTM 179.3m)
FCF Yield = 3.97% (FCF TTM 256.7m / Enterprise Value 6.46b)
FCF Margin = 5.93% (FCF TTM 256.7m / Revenue TTM 4.33b)
Net Margin = -1.86% (Net Income TTM -80.3m / Revenue TTM 4.33b)
Gross Margin = 35.73% ((Revenue TTM 4.33b - Cost of Revenue TTM 2.78b) / Revenue TTM)
Tobins Q-Ratio = 1.44 (Enterprise Value 6.46b / Book Value Of Equity 4.47b)
Interest Expense / Debt = 1.08% (Interest Expense 39.6m / Debt 3.68b)
Taxrate = 115.6% (set to none) (3.70m / 3.20m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.32 (Total Current Assets 2.62b / Total Current Liabilities 1.13b)
Debt / Equity = 0.82 (Debt 3.68b / last Quarter total Stockholder Equity 4.47b)
Debt / EBITDA = 6.02 (Net Debt 3.38b / EBITDA 611.4m)
Debt / FCF = 14.34 (Debt 3.68b / FCF TTM 256.7m)
Total Stockholder Equity = 4.43b (last 4 quarters mean)
RoA = -0.80% (Net Income -80.3m, Total Assets 10.09b )
RoE = -1.81% (Net Income TTM -80.3m / Total Stockholder Equity 4.43b)
RoCE = 3.51% (Ebit 282.6m / (Equity 4.43b + L.T.Debt 3.62b))
RoIC = 3.78% (Ebit 282.6m / (Assets 10.09b - Current Assets 2.62b))
WACC = unknown (E(3.23b)/V(6.91b) * Re(8.58%)) + (D(3.68b)/V(6.91b) * Rd(1.08%) * (1-Tc(none)))
Shares Correlation 3-Years: 87.03 | Cagr: 0.24%
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.24% ; FCFE base≈245.7m ; Y1≈260.4m ; Y5≈310.4m
Fair Price DCF = 35.72 (DCF Value 4.91b / Shares Outstanding 137.6m; 5y FCF grow 6.59% → 3.0% )
EPS Correlation: -14.89 | EPS CAGR: 0.65% | SUE: -0.09 | # QB: 0
Revenue Correlation: -65.05 | Revenue CAGR: -1.47% | SUE: -0.85 | # QB: 0
Additional Sources for PRGO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle